Completed PHASE3 INTERVENTIONAL 2-arm NCT02224313

Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women

Sponsor: Intira Sriprasert

Conditions Menopause

Interventions oral estradiol 1.0 mg oral progesterone 100 mg

Updated 12 times since 2017 Last updated: Mar 4, 2020 Started: Dec 31, 2015 Primary completion: Aug 31, 2018 Completion: Aug 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02224313, this PHASE3 trial focuses on Menopause and remains completed. Sponsored by Intira Sriprasert, it has been updated 12 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

12 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Dec 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 7 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Apr 2020 — Jan 2021 [monthly]

Completed PHASE3
Feb 2019 — Apr 2020 [monthly]

Completed PHASE3

Status: Unknown Status → Completed · Phase: NA → PHASE3
Sep 2018 — Feb 2019 [monthly]

Unknown Status NA

Status: Recruiting → Unknown Status
Jun 2018 — Sep 2018 [monthly]

Recruiting NA
Feb 2017 — Jun 2018 [monthly]

Recruiting NA
Jan 2017 — Feb 2017 [monthly]

Recruiting NA

First recorded

Dec 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Intira Sriprasert
TherapeuticsMD

Data source: Eastern Virginia Medical School

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Norfolk, United States